The ADVANCE in Japan

The ADVANCE in Japan, A longitudinal Study of age-related comorbidities in people with hemophilia - The ADVANCE in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030190046

Enrollment

600

Registered

2019-06-28

Start date

2019-02-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haemophilia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Mild, moderate or severe congenital Hemophilia A or B Age 40 years or over If informed consent is required by the regulations of each facility, consent must be obtained.

Exclusion criteria

Exclusion criteria: Acquired hemophilia Other coagulation disorder Patients with Factor VIII and Factor IX activity >40% at the time of diagnosis Under 40 years old If informed consent is required by the regulations of each facility, it is not possible to obtain it. If informed consent is not required, if the patient requests that the information cannot be provided

Design outcomes

Primary

Measure	Time frame
The principal objectives of the ADVANCE Study will be to determine the incidence rates of cardiovascular events.	—

Secondary

Measure	Time frame
To track the rates of anti-coagulation usage and death in PWH with CVD To compare the incidences and rates of death from CVD between PWH and a general male population To compare the incidence of CVD with the expected rates calculated from the CVD risk scores recorded at baseline To describe the incidences and rates of treatment for other comorbidities To compare the rates of comorbidities between PWH and a general male population To describe the management and outcomes To track the emergence of inhibitors over time in older PWH and their influence on cardiovascular events and the management of such events and To identify the causes of death in older PWH	—

Measure

Time frame

To track the rates of anti-coagulation usage and death in PWH with CVD To compare the incidences and rates of death from CVD between PWH and a general male population To compare the incidence of CVD with the expected rates calculated from the CVD risk scores recorded at baseline To describe the incidences and rates of treatment for other comorbidities To compare the rates of comorbidities between PWH and a general male population To describe the management and outcomes To track the emergence of inhibitors over time in older PWH and their influence on cardiovascular events and the management of such events and To identify the causes of death in older PWH

—

Contacts

Public ContactAzusa Nagao

Kansai Medical University Hospital

azusanagaooo@gmail.com+81-72-804-0101

Outcome results